Company Description
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.
The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 7, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Neal Walker |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 324 7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Interim Chief Executive Officer and Chairman |
| Kevin Balthaser | Chief Financial Officer |
| Dr. Joseph Monahan Ph.D. | Chief Scientific Officer |
| James Loerop | Chief Business Officer |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer and Director |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| Steve Tucker | Senior Vice President of Project Leadership |
| Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
| Dr. Steven Knapp M.S. Pharm.D. | Executive Vice President, Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 4, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |